Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ: MIRM )

50.04 -0.66 (-1.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou... 
Via Talk Markets
Analyst Expectations for Mirum Pharmaceuticals's Future
Via Benzinga
Mirum Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
Via Benzinga
Mirum Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for Mirum Pharmaceuticals's Future
Via Benzinga
Earnings Preview: Mirum Pharmaceuticals
Via Benzinga
Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
American Airlines, Cutera, Mirum Pharmaceuticals And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Panbela Therapeutics Shares Are Trading Higher By Around 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers TESSCO Technologies Incorporated (NASDAQ: TESS) shares jumped 86.8% to $8.78 as it agreed to be acquired by entities affiliated with Lee Equity Partners and Twin Point Capital for $9.00 in... 
Via Benzinga
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.